Keratitis - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 72 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Keratitis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Keratitis - Pipeline Review, H2 2014', provides an overview of the Keratitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Keratitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Keratitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Keratitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Keratitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Keratitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Keratitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Keratitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Keratitis Overview 7
Therapeutics Development 8
Pipeline Products for Keratitis - Overview 8
Pipeline Products for Keratitis - Comparative Analysis 9
Keratitis - Therapeutics under Development by Companies 10
Keratitis - Therapeutics under Investigation by Universities/Institutes 12
Keratitis - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Keratitis - Products under Development by Companies 15
Keratitis - Products under Investigation by Universities/Institutes 16
Keratitis - Companies Involved in Therapeutics Development 17
Adamis Pharmaceuticals Corporation 17
Cellceutix Corporation 18
Dompe Farmaceutici S.p.A. 19
Kala Pharmaceuticals, Inc. 20
Peregrine Pharmaceuticals, Inc. 21
RegeneRx Biopharmaceuticals, Inc. 22
Sirnaomics, Inc. 23
The Medicines Company 24
Keratitis - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
brilacidin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
C-31G - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
IBN-1 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
loteprednol etabonate - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
moxifloxacin hydrochloride - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
PGN-632 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
PIM-45 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Recombinant Human Nerve Growth Factor - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
RGN-259 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecules to Inhibit ATM for Herpes Keratitis - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
STP-601 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
targocil - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
tigecycline - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Keratitis - Recent Pipeline Updates 52
Keratitis - Dormant Projects 66
Keratitis - Product Development Milestones 67
Featured News & Press Releases 67
Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy 67
Jul 23, 2014: Dompe announces the Food and Drug Administration has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 68
Nov 04, 2013: Cellceutix to Pursue Significant Conjuctivitis and Kerititis Ocular Markets With Novel Antibiotic Brilacidin 68
Feb 14, 2013: Dompe Announces Enrollment Of First Patient In First International Clinical Trial Of rhNGF For Treatment Of Neurotrophic Keratitis 69
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 72
Disclaimer 72

List of Tables
Number of Products under Development for Keratitis, H2 2014 8
Number of Products under Development for Keratitis - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Keratitis - Pipeline by Adamis Pharmaceuticals Corporation, H2 2014 17
Keratitis - Pipeline by Cellceutix Corporation, H2 2014 18
Keratitis - Pipeline by Dompe Farmaceutici S.p.A., H2 2014 19
Keratitis - Pipeline by Kala Pharmaceuticals, Inc., H2 2014 20
Keratitis - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2014 21
Keratitis - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2014 22
Keratitis - Pipeline by Sirnaomics, Inc., H2 2014 23
Keratitis - Pipeline by The Medicines Company, H2 2014 24
Assessment by Monotherapy Products, H2 2014 25
Number of Products by Stage and Target, H2 2014 27
Number of Products by Stage and Mechanism of Action, H2 2014 29
Number of Products by Stage and Route of Administration, H2 2014 31
Number of Products by Stage and Molecule Type, H2 2014 33
Keratitis Therapeutics - Recent Pipeline Updates, H2 2014 52
Keratitis - Dormant Projects, H2 2014 66